Search research articles
Contact Us
Filters
Showing results (11-20 of 64) with videos related to
Page
of 7
Sort By:
Current Pharmaceutical Design
|
November 30, 2007
Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison
C Le Tourneau, E Raymond, S Faivre
Drugs
|
December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
E Raymond, S Faivre, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2005
mTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot, S Faivre, D Aguirre, et al.
Cancer Treatment Reviews
|
April 6, 1999
Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: a critical literature review
J Alexandre, S Faivre, W Sutherland, et al.
Revue Medicale Suisse
|
July 9, 2015
[Advanced hepatocellular carcinoma: importance of clinical trials]
V Aedo, V Cristina, E Raymond, et al.
Cancer Chemotherapy and Pharmacology
|
July 21, 1999
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
S Faivre, E Raymond, J M Woynarowski, et al.
L'Encephale
|
March 20, 2019
Vitamin D deficiency in a psychiatric population and correlation between vitamin D and CRP
S Faivre, N Roche, F Lacerre, et al.
British Journal of Cancer
|
September 18, 2008
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
C Le Tourneau, S Faivre, M Serova, et al.
Bulletin Du Cancer
|
May 20, 1998
[Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]
E Raymond, S Faivre, V Dieras, et al.
Bulletin Du Cancer
|
February 13, 2009
[Topics in mTOR pathway and its inhibitors]
C Dreyer, M-P Sablin, S Faivre, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 64) with videos related to
Sort By:
Page
of 7
Current Pharmaceutical Design
|
November 30, 2007
Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison
C Le Tourneau, E Raymond, S Faivre
Drugs
|
December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
E Raymond, S Faivre, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2005
mTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot, S Faivre, D Aguirre, et al.
Cancer Treatment Reviews
|
April 6, 1999
Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: a critical literature review
J Alexandre, S Faivre, W Sutherland, et al.
Revue Medicale Suisse
|
July 9, 2015
[Advanced hepatocellular carcinoma: importance of clinical trials]
V Aedo, V Cristina, E Raymond, et al.
Cancer Chemotherapy and Pharmacology
|
July 21, 1999
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
S Faivre, E Raymond, J M Woynarowski, et al.
L'Encephale
|
March 20, 2019
Vitamin D deficiency in a psychiatric population and correlation between vitamin D and CRP
S Faivre, N Roche, F Lacerre, et al.
British Journal of Cancer
|
September 18, 2008
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
C Le Tourneau, S Faivre, M Serova, et al.
Bulletin Du Cancer
|
May 20, 1998
[Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]
E Raymond, S Faivre, V Dieras, et al.
Bulletin Du Cancer
|
February 13, 2009
[Topics in mTOR pathway and its inhibitors]
C Dreyer, M-P Sablin, S Faivre, et al.
Page
of 7